Physician profile
Kara Lockcuff
NPI 1689448078
$6,218.93
in general payments reported to CMS, 2019-2025
25 companies · $3,290 in 2025
The $3,290 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $64.95 · 2024: $2,863 · 2025: $3,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,788 · Education: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,788.00 |
| Education | $430.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,238.85 | 2023-2025 | Tremfya |
| Abbvie INC. | $1,155.54 | 2024-2025 | |
| Amgen INC. | $934.66 | 2024-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $424.73 | 2024-2025 | Nemluvio |
| Leo Pharma INC. | $409.48 | 2024-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $361.45 | 2024-2025 | |
| Ucb, INC. | $263.97 | 2024-2025 | Bimzelx |
| Incyte Corporation | $248.32 | 2024-2025 | Opzelura |
| Lilly USA, LLC | $217.94 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Integra Lifesciences Corporation | $165.69 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Regeneron Healthcare Solutions, INC. | $136.80 | 2024-2025 | Dupixent, Libtayo |
| Organogenesis INC. | $133.17 | 2024-2025 | Novachor, Affinity |
| Mayne Pharma Commercial LLC | $90.82 | 2024-2025 | |
| Botanix Sb INC | $75.00 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $58.45 | 2024 | Sotyktu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $52.49 | 2025 | |
| Organon LLC | $49.36 | 2025 | |
| Novartis Pharmaceuticals Corporation | $45.46 | 2024-2025 | |
| Dermavant Sciences, INC. | $33.93 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.94 | 2025 | Spevigo |
| Journey Medical Corporation | $24.43 | 2024 | |
| Biofrontera INC. | $21.06 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Verrica Pharmaceuticals INC. | $17.74 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $17.05 | 2025 | Valchlor |
| Mimedx Group, INC. | $15.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Lockcuff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.